Senolytics has been studied in 2,068 papers since 2006: 31 trials and 63 observational studies in people, 750 in animals, 245 in cells, 934 reviews; 575 in the past year. The newest story, Nov 16, 2026: “Protein levels alter drug sensitivity in lab-grown human cells”.
Fisetin extends yeast lifespan and reduces senescence in human cells across independent labs, but a study in naturally aging female mice shows no clear survival or physical-function effect. A human trial reports reduced senescence and increased MASH resolution with dasatinib–quercetin. Dasatinib–quercetin increases demyelination in mice; 3 of 22 aging trials have developer sponsorship.
2,628 findings in 1,146 papers from 2007 to 2026, 141 of them since April 2026
Independent labs found the same change in cells, worms or flies, mice and people. 328 independent labs in 42 countries; 25 trials, 25 about aging, 1 with no results posted.
“the difference between UBX1325 and sham in mean change to week 48 in best corrected visual acuity was 5.6 more ETDRS letters (95% confidence interval, -1.5 to 12.7)”
Cells, worms or flies, mice and humans: replicated by independent labs.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
328 independent labs in 42 countries
111 findings against
25 trials, 25 about aging, 1 with no results posted
DrugAge records 4 results from 4 papers: 2 in mice, 1 in D. melanogaster and 1 in S. cerevisiae. Average lifespan is the mean or the median, as each paper reports it.
Studies of senolytics measured 525 outcomes; the most studied are cellular senescence (71 studies), inflammation (27) and senescent cells (19).
Cellular senescence
↓downin mice27↓downin reviews17↓downin human cells12↓downin rats5+7−80%
71 studies
Dasatinib + quercetin decreases cellular senescence in humans (measured by single-nucleus RNA sequencing).
“Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group.”
Human trialmeasured by single-nucleus RNA sequencing
Senolytics decrease cellular senescence in silico (Simulated coupled cellular–matrix system with illustrative parameters) (Cellular state s∗ = 0.651 to s∗ = 0.125).
“a single senolytic course flips the cellular state from the senescentfixed point (s∗ = 0.651) back to the healthy one (s∗ = 0.125)”
In silicoSimulated coupled cellular–matrix system with illustrative parametersAbove a critical dose (D50 ≈ 0.97; units not stated)single course
Dasatinib + quercetin decreases inflammation in humans.
“Transcriptomic analysis of RNA isolated from PBMC samples revealed baseline to post-treatment downregulation of seven of the 19 inflammatory related genes included in the CTRA transcriptomic stress profile.”
“Early findings in animal models and in human cell lines suggest that fisetin has the potential to mitigate age-related diseases by targeting chronic inflammation”
Senolytics decrease inflammation in animal models of TBI.
“therapeutically targeting of senescent cells through administration of senolytic drugs in animal models leads to attenuated neuroinflammation and neurodegeneration in the injured brain”
Senolytics decrease inflammation in aged mice and mice with MASLD.
“senolytic treatment targeting senescent macrophages reduced liver inflammation and steatosis in both aged mice and mice with metabolic dysfunction-associated steatotic liver disease.”
Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in human fetal lung explants exposed to cannabinoids and nicotine.
“The addition of senolytics, Dasatinib and Quercetin (D + Q), reduced the senescence-associated secretory phenotype (SASP), such as IL-6, IL-8, M-CSF, MCP-3, MIP-1β, TNFα, MIP-3β, and TSLP”
Cellsin human fetal lung explants exposed to cannabinoids and nicotinelung
Zenodo (CERN European Organization for Nuclear Research)·Preprint
Fisetin decreases senescence-associated secretory phenotype (SASP) in humans (preliminary human studies).
“Preliminary human studies involving FOXO4-axis modulators, such as high-dose fisetin, show a reduction in the senescence-associated secretory phenotype (SASP)”
Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in rats (aged rats with rotator cuff tear repair).
“a significant decrease in the gene expression of senescence markers (p21 and p16) and senescence-associated secretory phenotype factors (IL-6, IL-1β, and MMP-3)”
Animalsaged rats with rotator cuff tear repairsupraspinatus-humerus complex12 weeks after repairn = 24
FOXO4-DRI induces apoptosis in senescent endothelial cells.
“FOXO4-DRI prevents the binding of FOXO4 to P53, facilitating the phosphorylated P53 nuclear exclusion, which subsequently trigger BAX and cleaved caspase-3, leading to the apoptosis of senescent cells.”
↑upin mice4↔no changein rats2↑upin reviews2↑upin M. models1+1
10 studies
Dasatinib + quercetin improves cognitive function in mice (TDP-43 Q331K mice).
“we obtained robust target engagement, rescued cognitive impairment, restored motor unit function, and ameliorated muscle strength and fiber pathology.”
FOXO4-DRI improves cognitive function in M. models.
“administering FOXO4-DRI decreases the accumulation of senescent cells, restores cerebral blood flow and the integrity of the blood-brain barrier (BBB), reverses hippocampal atrophy, and enhances cognitive function.”
Senolytics improve cognitive function (preclinical models of AD).
“Senolytics, which selectively eliminate senescent cells, have demonstrated benefit in multiple preclinical models of AD, including decreased neuroinflammation, improvement in neuronal function and cognitive performance.”
Senolytics decrease senescent cell burden in mice following disuse.
“Senolytic treatment reduced overall senescent cell burden, attenuated macrophage accumulation, and restored muscle mass and function in aged mice following disuse.”
Dasatinib + quercetin decreases senescent cell burden in mice (surgery-induced, in aged mice).
“Intermittent treatment of the mice with the senolytic drugs dasatinib and quercetin (D/Q) showed a significant reduction in surgery-induced senescent cell burden.”
“Emerging strategies such as epigenetic reprogramming, gene editing, stem cell therapy, and senolytic drugs show immense promise in extending health spans”
Senolytics decrease bone loss in preclinical studies.
“Preclinical studies using pharmacological and genetic clearance of senescent cells and suppression of the senescence associated proinflammatory signature lays the foundation for exploring these strategies as therapeutic interventions that could mitigate BMAd and associated bone loss.”
Current opinion in endocrine and metabolic research·
Dasatinib + quercetin prevents bone loss (chemotherapy-induced bone loss).
“treatment with the senolytic combination dasatinib and quercetin (D + Q) selectively eliminates senescent CAR cells and BMAds, effectively preventing chemotherapy-induced bone loss”
Dasatinib + quercetin decreases TNF-alpha in humans (-3.0% (95% CI -13.0 to 7.1), non-significant).
“Mean percent change in tumour necrosis factor-alpha (TNF-α), a key product of the senescence-associated secretory phenotype (SASP), non-significantly decreased following DQ by -3.0% (95% CI: -13.0, 7.1)”
Dasatinib + quercetin decreases TNF-alpha in humans.
“The mean percent reduction in TNF-α was significantly different (p = 0.04) than the mean percent change in the Biomarker Control group (mean percent change = 16.8, 95% CI: −1.7, 35.4).”
Fisetin showed no clear effect on serious adverse events in humans (CVID-associated GLILD; fisetin versus placebo) (No serious adverse events in either group; one mild diarrhea episode in each group).
“No serious adverse events occurred, and one mild diarrhea episode occurred in each group.”
Human trialCVID-associated GLILD; fisetin versus placebo20 mg/kg180 daysn = 10
Fisetin showed no clear effect on frailty score in humans (CVID-associated GLILD; within fisetin group) (Median score unchanged with fisetin; increased by 2 points with placebo).
“Median frailty score remained unchanged with fisetin but increased by 2 points with placebo.”
Human trialCVID-associated GLILD; within fisetin group20 mg/kg on days 0, 1, 28, and 29n = 10
Fisetin is associated with senescence and SASP biomarkers in humans.
“potential of fisetin and quercetin to modulate senescence and SASP biomarkers in animal models of aging and progeria, as well as in interventional studies involving human subjects”
Fisetin is associated with cancer-related microRNA expression in colon cancer cell lines.
“We identified three phytochemicals (fisetin, glabridin, and silibinin) that suppressed cell proliferation and were associated with changes in cancer-related miRNA expression in colon cancer cells.”
Dasatinib + quercetin is associated with lipid profile in humans (modest).
“Mass spectrometry indicated stable levels of amyloid β and tau proteins in CSF, unchanged urinary metabolites, and modest treatment-associated lipid profile changes”
National Institute on Aging$15MJapan Society for the Promotion of Science¥239MNational Institute of Arthritis and Musculoskeletal and Skin Diseases$3.4M
Preprints report that fisetin extends worm lifespan; independent labs reproduce reduced senescence with dasatinib plus quercetin in human cells. Mouse studies of experimental autoimmune encephalomyelitis report improved survival but also unchanged clinical outcomes with dasatinib plus quercetin. Nineteen registered trials concern aging; Unity Biotechnology sponsors one, and some papers declare company ties.
Summary rewritten as its findings changed.
As it read before
Independent labs reproduce senescence-marker reductions in cells and mice; a human trial reports fibrotic MASH resolution, with human work from one group. Mouse immune-response results include activation and no effect; frailty increases in rTg4510 mice. Twelve of 65 trials lack results over a year after ending; five findings declare maker interests, and AbbVie and Genentech sponsor 17 trials.
Summary rewritten as its findings changed.
As it read before
In a human trial of fibrotic MASH, dasatinib plus quercetin clears liver senescence, reduces fibrosis, and promotes disease resolution. Cellular, zebrafish, and mouse studies further show senolytics suppress senescence markers, senescent cells, and pathogenic immune phenotypes.
Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.
Median survival after human glioblastoma implantation was 40 days in young mice, compared with 33 days in older mice.Median survival after human glioblastoma implantation was 40 days in young mice, compared with 33 days in older mice.
Animal experiments found that aging and chronic ultraviolet B exposure changed the skin environment in ways that favored tumor growth.Animal experiments found that aging and chronic ultraviolet B exposure changed the skin environment in ways that favored tumor growth.
Quercetin and dasatinib improved thinking and muscle function in genetically modified mice used to model amyotrophic lateral sclerosis, a disease affecting movement.Quercetin and dasatinib improved thinking and muscle function in genetically modified mice used to model amyotrophic lateral sclerosis, a disease affecting movement.